Profoundbio Inc. closed a $70 million series A financing round that will see it advance its two lead antibody-drug conjugate (ADC) programs to the clinic. The Suzhou, China, and Woodinville, Wash.-based company has raised a total of more than $138 million in the past two years.
Turning Point Therapeutics Inc. has picked up near-global rights to develop and commercialize an antibody drug conjugate (ADC) targeting Claudin18.2 from Lanova Medicines Ltd. for $25 million up front. The deal excludes greater China and South Korea.
Turning Point Therapeutics Inc. has picked up near-global rights to develop and commercialize an antibody drug conjugate (ADC) targeting Claudin18.2 from Lanova Medicines Ltd. for $25 million up front. The deal excludes greater China and South Korea.
Tubulis GmbH has added considerable momentum to its effort to build a pipeline of novel antibody-drug conjugates (ADCs) by closing a €60 million (US$63.2 million) series B round. CEO and co-founder Dominik Schumacher told BioWorld the cash would enable the Munich-based firm to generate clinical proof of concept, build a clinical pipeline and continue development of its platform technologies.
Genequantum Healthcare Co. Ltd. will work with Aimedbio Inc. to co-develop an antibody-drug conjugate (ADC) to treat brain and other cancers, working toward an IND filing in 2023. Aimedbio will focus on antibody development, while Genequantum will work on linker-payload development. “Since we have a plan to market and sell the product globally, we will conduct a phase I clinical trial in the U.S., Australia, South Korea, and China as a priority,” Do-Hyun Nam, founder, chairman, and chief technology officer of Aimedbio, told BioWorld.
Genequantum Healthcare Co. Ltd. will work with Aimedbio Inc. to co-develop an antibody-drug conjugate (ADC) to treat brain and other cancers, working toward an IND filing in 2023.
With 11 approved therapeutics in a diversity of targets and indications, antibody-drug conjugates (ADCs) have proved their clinical mettle. But they have not yet reached their full clinical potential, which, in the opinion of Astrazeneca plc’s Kenneth Thress, could transform patient care. The strength of ADCs, he told the audience at an educational session at the 2022 annual meeting of the American Association for Cancer Research (AACR 2022), is that it can turn anything into a targeted therapy.
Less than a year after winning approval in China for the first domestically developed antibody-drug conjugate (ADC), Remegen Co. Ltd. raised ¥2.6 billion (US$410 million) and picked up a listing on the Shanghai STAR market to support further work on its monoclonal antibodies and ADCs.
Less than a year after winning approval in China for the first domestically developed antibody-drug conjugate (ADC), Remegen Co. Ltd. raised ¥2.6 billion (US$410 million) and picked up a listing on the Shanghai STAR market to support further work on its monoclonal antibodies and ADCs.
After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).
RSS
